Pharmaceutical Market Europe • April 2021 • 38-40
APPOINTMENTS
Genentech
LILLI PETRUZZELLI
Roche’s Genentech division has appointed Lilli Petruzzelli as senior vice president, early clinical development for Genentech’s Research and Early Development organisation (gRED). Petruzzelli joins the pharma company from Incyte, where she previously held the role of group vice president, early clinical development for over a year. Prior to that, she worked as the vice president for translational clinical oncology for a period of five years at Novartis. Before that, she served as site head oncology translational medicine at the Swiss pharma company. In her new role at Genentech, Petruzzelli will lead gRED teams in the development of novel clinical drug candidates. In addition, she will aid in the process of bringing investigational candidates that are ready for the clinic through to late-stage development.
Merck & Co
CAROLINE LITCHFIELD
Merck & Co – known as MSD outside the US and Canada – has appointed Caroline Litchfield as executive vice president and chief financial officer. Currently, Litchfield is the company’s treasurer, with responsibility for Human Health. She first joined Merck in its UK business in 1990 and has held a number of positions of increasing responsibility at the company.
Merck & Co
FRANK CLYBURN
Merck & Co has also appointed Frank Clyburn as president, Human Health. Prior to this, Clyburn was Merck’s chief commercial officer for Human Health and Merck’s president, global oncology. In his new role, he will be responsible for all Human Health marketing and commercial operations globally and the P&L for the company’s portfolio of medicines and vaccines.
Moderna
JONATHAN HOGGATT
Jonathan Hoggatt has joined Moderna as director of haematology. Hoggatt was previously a principal faculty member at the Harvard Stem Cell Institute, where he ran his own research unit – the Hoggatt lab – which is focused on tissue regeneration and stem cell biology, with a particular focus on translational research to enhance bone marrow transplantation.
Novartis
KAREN HALE
Karen Hale has been named chief legal officer for Swiss pharma company Novartis. Hale brings over 20 years of global legal and compliance experience in the pharma industry to Novartis.
After joining Abbot in 1997, she remained with the company when it became AbbVie and has held roles at AbbVie as VP, deputy general counsel, and chief ethics and compliance officer.
Enterome
ANNE DAGALLIER
French biopharma company Enterome has appointed Anne Dagallier as chief business officer. Dagallier has over 22 years of experience in global business and drug development and joins the company after spending 19 years at Sanofi, where she held several scientific and senior business development positions, including head of consumer health care alliances and in-licences.
Ermium Therapeutics
ANNEGRET VAN DER AA
Annegret Van der Aa has joined Ermium Therapeutics as chief scientific officer and chief development officer. Van der Aaa has nearly 20 years of broad R&D experience working at small and mid-sized biotech companies, including Innogenetics, ActoGeniX, OCTIMET Oncology and Galapagos , where she worked on the clinical development of Jyseleca (filgotinib).
eTheRNA
VOLKER GERMASCHEWSKI
Clinical-stage company eTheRNA immunotherapies has appointed Volker Germaschewski as senior vice president for R&D. He joins eTheRNA from Kymab,
where he initially served as senior director of discovery and subsequently worked as vice president of haematology. Prior to that, Germaschewski held several positions in biopharma R&D at GlaxoSmithKline.
Hansa Biopharma
MAGNUS KORSGREN
Hansa Biopharma has appointed Magnus Korsgren as vice president and head of research and development. Korsgren has an extensive background gained from working in the life sciences industry and academia. He has over 15 years of experience from leadership positions across a number of pharma and biotech companies, including Ferring, AstraZeneca, BioInvent and Novartis.
Inotrem
SVEN ZIMMERMANN
Paris-headquartered biotech company Inotrem has appointed Sven Zimmermann as chief executive officer. Zimmermann brings extensive leadership in biotech companies’ financial and commercial strategy to the role. Prior to joining Inotrem, he served as CFO at Swiss biopharma company MetrioPharm and also worked for UBS Investment Bank.
Alligator Therapeutics
SØREN BREGENHOLT
Søren Bregenholt has been appointed as chief executive office at Swedish biotech company Alligator Therapeutics. Bregenholt most recently served as CEO and board director at Macrophage Pharma in the UK. Additionally, he previously worked in corporate vice president positions at Novo Nordisk, and also previously served as chief operating officer at Symphogen.
Orphazyme
CHRISTOPHE BOURDON
Danish biopharma company Orphazyme has appointed Christophe Bourdon as chief executive officer. Bourdon has 25 years of experience in the biotech/pharmaceutical industry, including as Amgen’s senior VP, general manager, US oncology. Prior to this, he served as Alexion’s senior VP of Europe, Middle East, Africa and Canada.
Augustine Therapeutics
SYLVAIN CELANIRE
Augustine Therapeutics has appointed Sylvain Celanire as chief executive officer. Celanire has extensive biopharmaceutical expertise with over 20 years of experience in drug discovery. He co-founded French biotech company Pragma Therapeutics and has held roles at Addex Pharmaceutical and UCB New Medicines.
Immunicum AB
JEROEN ROVERS
Immunicum AB has named Jeroen Rovers as chief medical officer. Prior to this, Rovers served as chief medical officer at DCprime before transitioning to the role of managing director after the business combination with Immunicum. Prior to DCprime, he was chief medical officer at Kiadis and also held the role of chief medical officer at Ceronco Biosciences.
Gyroscope Therapeutics
JESSICA STITT
Gyroscope Therapeutics has appointed Jessica Stitt as chief financial officer. Stitt brings over two decades of healthcare finance and leadership experience to the role. Most recently, she served as the VP of finance and operation for cardiovascular disease specialist MyoKardia, recently acquired by Bristol Myers Squibb, and also as VP of finance and investor relations for Theravance Biopharma.
Shorla Pharma
NICHOLAS HOLSMAN
Nicholas Holsman has been appointed as chief commercial officer at Shorla Pharma. Holsman has almost 20 years of experience in leading commercial functions, with a focus on high growth start-up biotech companies. Most recently, he served as head of commercial operations at Oncopeptides and as senior director of commercial strategy and market access at KemPharm.
Bicycle Therapeutics
JOSE-CARLOS GUTIERREZ-RAMOS
Bicycle Therapeutics has appointed Jose-Carlos Gutierrez-Ramos to its board of directors. Currently, Gutierrez-Ramos serves as chief scientific officer of the Danaher Corporation. He was previously head of global drug discovery at AbbVie and group senior VP, biotherapeutics R&D at Pfizer. He was also the founding CEO and president of Repertoire Immune Medicine.
Nordic Nanovector
PETER BRAUN
Oslo-based Nordic Nanovector has appointed Peter Braun as chief executive officer. Braun has extensive commercialisation experience with oncology product and knowledge of pharmaceutical markets worldwide from a nearly 30-year career at Roche, where he held various operational leadership positions and multiple commercial roles in Europe, the US and Latin America.
Nabriva Therapeutics
DANIEL DOLAN
Nabriva Therapeutics has appointed Daniel Dolan as chief financial officer. Dolan brings over 20 years of global, corporate finance and executive management experience to the role. Most recently, he served as principle financial officer of Radius Health. Before that, Dolan had a 12-year career at Shire Pharmaceuticals, which was acquired by Takeda in 2019.
4D Pharma
JOHN BECK
John Beck has joined Leeds-headquartered 4D Pharma as chief financial officer. Beck brings over 30 years of experience in the financial and biopharmaceutical industries to his role at 4D. Previously he was the senior VP, finance and CFO of Ritter Pharmaceuticals and executive manager and chief executive manager at Wellspring Water Technologies.
Freeline Therapeutics
COLIN LOVE
London, UK-based Freeline Therapeutics has appointed Colin Love to its board of directors. Love has over 30 years of experience leading biopharmaceutical company operations. He currently works as the chief operating officer and co-founder of Replimune, where he has served since 2015. Prior to this, he was a vice president of clinical operations at Amgen.
McCann Health
ADRIANO BOTTER
McCann Health has promoted Adriano Botter to the new role of global chief digital officer. Prior to taking on the new role, Botter was digital director for McCann Health Brazil. As digital director, he developed partnerships with big technology and social media companies. He has 14 years of experience in advertising, having worked for various agencies within WPP and IPD.
Lucid Group
SALLY STRINGER
Lucid Group has promoted Sally Stringer to managing partner of Team HealthCare21. Stringer joined the HealthCare21 team in 2013 as an editorial team leader, before taking on the roles of scientific director and subsequently executive scientific director. Prior to this, she worked as a senior medical writer at Prime-Medica. Stringer is also an honourary senior lecturer at Manchester University.
Langland
MIKE BRIGHTLEY
Langland has appointed Mike Brightley as creative director. Brightley has over 14 years of healthcare advertising experience, having previously worked at Ogilvy Healthworld, PAN and most recently as associate creative director at TBWA\WorldHealth. During his career, Brightley has worked on a number of campaigns, and has applied emotion-recognition technology for adaptive storytelling.
Syneos Health Communications
ORRIN POLLARD
AND MARK SUDWELL
Syneos Health Communications has appointed Orrin Pollard and Mark Sudwell to its team. Pollard joins as director of European creative expression and previously spent over ten years as founder and creative director of DDB Remedy UK. Sudwell has been appointed as head of value, access and reputation communications and he brings over 20 years of experience to the role.
Syneos Health Communications
TANYA VON AHLEFELDT
AND JENNY FANSTONE
Also joining Syneos is Tanya von Ahlefeldt and Jenny Fanstone, who have been appointed as European senior director, public relations and scientific director, respectively. Most recently, Von Ahlefeldt set up the internal and external offering for a medical education agency. Fanstone brings over 20 years of experience in medical writing and strategic communication to Syneos.
Syneos Health Communications
CHRISTOPHER HUBERT
AND SANDY LEE
Rounding out the appointments at Syneos are Christopher Hubert and Sandy Lee. Hubert joins as senior art director with 20 years of advertising experience, having previously run campaigns for various blue chip companies. Lee, who joins as senior account director and social media lead, has previously led global campaigns for the World Health Organization, The Global Fund and more.
GCI Health
KIM WALKER
GCI Health has appointed Kim Walker as joint managing director, UK. For the last two years, Walker has served as deputy managing director in the UK for GCI Health. Following her promotion, Walker will be responsible for growing the healthcare communications agency’s network in the UK, and will also continue to drive operations and marketing for the agency.
GCI Health
HANNAH MORRIS
Hannah Morris has also been promoted to the role of joint managing director, UK at GCI Health. Previously, Morris worked as head of client services UK for the agency, with a track record of delivering behaviour-changing campaigns for clients. Prior to joining GCI Health, Morris worked as practice director at Ketchum Public Relations and account director at Red Door Communications.
GCI Health
CLARE YIANNI
GCI Health has also named Clare Yianni as chief of staff. Prior to taking on this role, Yianni served as operations director of GCI Health UK. In her new role, she will support the agency’s efforts to build out its European capability. Before joining GCI Health, Yianni worked at pharmaceutical company MSD as a strategic project manager.
Lucid Group
TANYA GOODYEAR AnD CHERYL HARRISON DOYLE
Lucid Group has also promoted Tanya Goodyear and Cheryl Harrison Doyle to new roles as director of innovation and technology and global asset strategy director, respectively. Before moving into her new role, Goodyear was managing partner for Lucid’s medcomms team Origins. Previously, Harrison Doyle was client partnership director at the company.
Page & Page and Partners
CHARLOTTE SALE
Charlotte Sale has joined Page & Page and Partners as senior account director. Sale has significant experience gained from working within the healthcare industry, having previously worked for major pharmaceutical and dental manufacturers for over 14 years. She will join the client services team to lead and manage ‘the continued delivery of excellence’ across new and existing clients.
Ashfield Engage
KEITH BUCKBY
Ashfield Engage has announced the appointment of Keith Buckby as UK business development director. Buckby returns to Ashfield Engage – part of UDG Healthcare – after having previously worked for Ashfield for over 11 years across a number of operational roles. Prior to returning to Ashfield, Buckby completed a two-year stint at IQVIA, where he most recently held the role of business development director.